Financing - April 11, 2022
Moberg Pharma carries out a fully guaranteed issue
The Board of Directors of Moberg Pharma has resolved to carry out a fully guaranteed issue of new ordinary shares with preferential rights for existing shareholders of approximately SEK 121 million before transaction costs. The Rights Issue is conditional upon approval at an extraordinary general meeting, states the company. “The financing we have secured gives […]
In a new job - August 12, 2020
Moberg Pharma appoints new Chief Medical Officer
Moberg Pharma announces the appointment of Cindy Wong as Chief Medical Officer. Wong will during the fall be joining the management team at Moberg Pharma coming from a previous position as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH. International experience in clinical development and registration of new products Wong brings […]
Agreement - March 24, 2020
Moberg Pharma enters financing agreement
Moberg Pharma enters financing agreement of up to 216 million SEK for further investments in MOB-015. Moberg Pharma has entered into a convertible note agreement with Nice & Green S.A., contingent on an authorization at an Extraordinary General Meeting. In December 2019, the company reported that the primary endpoint for MOB-015 was met in the […]
Clinical Trials - January 22, 2020
Update on Moberg Pharma Trial
Moberg Pharma has completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and increased the understanding of the study outcomes. Key conclusions include: i) MOB-015 delivers a very high mycological cure rate […]
Clinical Trials - December 12, 2019
Surprising results from Moberg Pharma – resulting in stock market fall
Monday December 9th, Moberg Pharma announced results from the first study in the Phase 3 program for MOB-015, where the primary endpoint and the two key secondary endpoints were met. However, the results were somewhat contradictory and the company has clarified the various study parameters as well as their view of the current status and […]
Agreement - October 21, 2019
Moberg Pharma and Dongkoo sign agreement
Moberg Pharma has signed a distribution agreement with DongKoo Bio & Pharma for MOB-015 in the Republic of Korea. Under the agreement DongKoo is granted exclusive rights to market and sell MOB-015 in the Republic of Korea. Moberg Pharma assumes production and supply responsibility. DongKoo will conduct registration activities in the Republic of Korea, and […]
